Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents

Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Francis J. Giles

Resultado de la investigación: Review articlerevisión exhaustiva

6 Citas (Scopus)

Resumen

Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of BcrAbl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.

Idioma originalEnglish (US)
Páginas (desde-hasta)1399-1413
Número de páginas15
PublicaciónLeukemia and Lymphoma
Volumen51
N.º8
DOI
EstadoPublished - ago. 2010

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents'. En conjunto forman una huella única.

Citar esto